Pierrel S.p.A. is a global provider to the pharmaceutical and life science industries, specialized specialized in clinical development, registration and licensing of new drugs or formulations and in pharmaceutical production , through its Contract Research , Contract Manufacturing and Pharma Divisions.
Pierrel Group, with over 60 years of experience in the pharmaceutical sector, is one of the main European manufacturers of local and dental anesthetic drug products. Pierrel SpA is listed on the Italian Stock Exchange market since 2006 More.
Pierrel Pharma S.r.l. is responsible for sales and marketing of Orabloc in the US and Canada through a network of established and respected distributors of dental products More.
Orabloc— A New Articaine in the USA
Rapid onset of anestesia within 1-9 minutes
Complete anesthesia lasts about 1 hour for infiltration, up to 2 hours for nerve block
Only 10% overage of epinephrine1
A 24 month shelf life at room temperature
Very low manufacture related degradation products such as articaine acid and epinephrine sulphonic acid
Sodium edentate free, methylparaben free and latex free
Each OrablocTM individual cartridge is blister packed for maximum protection during storage and handling
WARNING AND PRECAUTIONS
OrablocTM is an amide local anesthetic containing a vasoconstrictor indicated for local, infiltrative, or conductive anesthesia in both simple and complex dental procedures.
OrablocTM contains sodium metabisulfite. OrablocTM is contraindicated in patients who are hypersensitive to products containing sulfites. Products containing sulfites may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people.
1The American Heart Association (AHA) reccomends using the lowest possible quantity of epinephrine (Kaplan EL ed. Cardiovascular disease in dental practice. Dallas, TX: American Heart Association, 1986.)